Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT ID: NCT05840211
Last Updated: 2025-10-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
654 participants
INTERVENTIONAL
2023-05-08
2028-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT07018427
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
NCT04639986
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer
NCT03901339
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
NCT04448886
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sacituzumab Govitecan-hziy (SG)
Participants will receive SG at a dose of 10 mg/kg infusion on Days 1 and 8 of a 21-day cycle.
Sacituzumab Govitecan-hziy
Administered intravenously
Treatment of Physician's Choice (TPC)
Participants will receive TPC determined prior to randomization to 1 of the 3 allowed regimens:
* paclitaxel 80 mg/m\^2 over 1 hour (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle.
* nab-Paclitaxel 100 mg/m\^2 over 30 minutes (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle.
* capecitabine at 1000-1250 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period of a 21-day cycle.
Paclitaxel
Administered intravenously
Nab-paclitaxel
Administered intravenously
Capecitabine
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab Govitecan-hziy
Administered intravenously
Paclitaxel
Administered intravenously
Nab-paclitaxel
Administered intravenously
Capecitabine
Administered orally
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have adequate tumor tissue sample preferably from locally recurrent or metastatic site.
* Documented evidence of HR+ metastatic breast cancer (mBC) confirmed with the most recently available tumor biopsy preferably from a locally recurrent or metastatic site.
* Documented evidence of HER2- status.
* Documented PD by computed tomography (CT) or magnetic resonance imaging during or after the most recent therapy per RECIST v1.1 criteria.
* Candidate for the first chemotherapy in the locally advanced or metastatic setting.
* Eligible for capecitabine, nab-paclitaxel, or paclitaxel.
* Individuals must have at least one of the following:
* Disease progression on at least 2 or more previous lines of endocrine therapy (ET) with or without a targeted therapy in the metastatic setting.
* Disease recurrence while on the first 24 months of starting adjuvant ET will be considered a line of therapy; these individuals will only require 1 line of ET in the metastatic setting.
* Disease progression within 6 months of starting first-line ET with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor (if ineligible or if unable to access a CDK 4/6 inhibitor) in the metastatic setting.
* Disease recurrence while on the first 24 months of starting adjuvant ET with CDK 4/6 inhibitor and if the individual is no longer a candidate for additional ET in the metastatic setting.
* Individuals may have received prior targeted therapies, including but not limited to PARP inhibitors (for those with germline BRCA1 or BRCA2 mutations), phosphatidylinositol 3-kinase (PI3K) inhibitors (for those with PIK3CA mutations), or mammalian target of rapamycin (mTOR) inhibitors. However, individuals can no longer be candidates for additional endocrine treatment with or without targeted therapies.
* Individuals with HIV must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease.
* Demonstrates adequate organ function.
* Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria
* Locally advanced metastatic breast cancer (mBC) (Stage IIIc) in individuals who are candidates for curative intent therapy at the time of study enrollment.
* Current enrollment in another clinical study and use of any investigational device or drug (drugs not marketed for any indication) either within 5 half-lives or 28 days prior to randomization, whichever is longer.
* Use of investigational drugs in the category of Selective Estrogen Receptor Degraders are acceptable if last dose was longer than 14 days prior to randomization.
* Received any prior treatment (including antibody-drug conjugate (ADC)) containing a chemotherapeutic agent targeting topoisomerase I.
* Received any prior treatment with a trophoblast cell-surface antigen 2 (Trop-2)-directed ADC.
* Have an active second malignancy.
* Have an active serious infection requiring antibiotics.
* Have active hepatitis B virus (HBV) or hepatitis C virus (HCV).
* Individuals positive for human immunodeficiency virus type 1/2 (HIV-1 or -2) with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
* Have a positive serum pregnancy test or are breastfeeding for individuals who are assigned female at birth.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilead Study Director
Role: STUDY_DIRECTOR
Gilead Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
Chandler, Arizona, United States
Los Angeles Hematology Oncology Medical Group
Los Angeles, California, United States
Stanford Cancer Institute
Palo Alto, California, United States
University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Rocky Mountain Cancer Centers, LLP
Littleton, Colorado, United States
Yale-New Haven Hospital-Yale Cancer Center
New Haven, Connecticut, United States
Investigational Drug Services, AdventHealth Orlando
Altamonte Springs, Florida, United States
Florida Cancer Specialists
Brooksville, Florida, United States
Florida Cancer Specialist
Leesburg, Florida, United States
Florida Cancer Specialist
St. Petersburg, Florida, United States
Piedmont Cancer Institute
Atlanta, Georgia, United States
Georgia Cancer Specialist - Annex
Atlanta, Georgia, United States
Northwest Georgia Oncology Centers
Marietta, Georgia, United States
The University of Kansas Hospital
Kansas City, Kansas, United States
Hematology Oncology Clinic
Baton Rouge, Louisiana, United States
Saint Luke's Cancer Institute
Kansas City, Missouri, United States
David C. Pratt Cancer Center
St Louis, Missouri, United States
Astera Cancer Care
East Brunswick, New Jersey, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio, United States
Penn State Cancer Institute
Hershey, Pennsylvania, United States
Magee-Womens of UPMC
Pittsburgh, Pennsylvania, United States
Prisma Health - Upstate
Greenville, South Carolina, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Vanderbilt University Medical Center - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
US Oncology Investigational Products Center (IPC)
Fairfax, Virginia, United States
US Oncology Investigational Products Center (IPC)
Norfolk, Virginia, United States
MultiCare Regional Cancer Center - Auburn
Auburn, Washington, United States
Hospital Britanico de Buenos Aires
Buenos Aires, , Argentina
Instituto de Investigaciones Clinicas de Mar del Plata
Buenos Aires, , Argentina
Instituto Alexander Fleming
C.a.b.a., , Argentina
Hospital Alemán
CABA, , Argentina
Centro Privado de RMI Rio Cuarto S.A.
Córdoba, , Argentina
Instituto de Oncología de Rosario
Rosario, , Argentina
CER San Juan Centro Polivalente de Asistencia e Investigación Clínica
San Juan, , Argentina
Royal Brisbane and Women's Hospital
Queensland, ME, Australia
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
GenesisCare North Shore (Oncology)
St Leonards, New South Wales, Australia
Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Icon Cancer Centre Hobart
Hobart, Tasmania, Australia
Austin Health
Melbourne, Victoria, Australia
Sunshine Hospital (Western Health)
St Albans, Victoria, Australia
Breast Cancer Research Centre - WA
Nedlands, Western Australia, Australia
University Hospital Innsbruck
Innsbruck, , Austria
Universitätsklinik für Innere Medizin 3 der PMU
Salzburg, , Austria
Medizinische Universitat Wien, Univ. Klinik fur Innere Medizin I Klinische Abteilung fur Onkologie
Vienna, , Austria
Klinikum Wels-Grieskirchen
Wels, , Austria
GZA Ziekenhuizen - Campus Sint-Augustinus
Antwerp, , Belgium
AZ Klina
Brasschaat, , Belgium
Cliniques Universitaires Saint-Luc
Brussels, , Belgium
Universitaire Ziekenhuis Leuven
Leuven, , Belgium
CHU UCL Namur-Site STE. Elisabeth
Namur, , Belgium
Hospital Haroldo Juaçaba - Instituto do Câncer do Ceará
Fortaleza, , Brazil
Hospital Araujo Jorge - Associacao de Combate ao Cancer em Goias
Goiânia, , Brazil
Oncosite - Centro de Pesquisa Clinica e Oncologia
Ijuí, , Brazil
Catarina Pesquisa Clinica
Itajaí, , Brazil
Oncoclinicas do Brasil Servicos Medicos AS
Minas Gerais, , Brazil
Liga Norte-Rio-Grandense Contra o Câncer
Natal, , Brazil
CIONC-Centro Integrado de Oncologia de Curitiba
Paraana, , Brazil
Hospital Erasto Gaertner
Paraná, , Brazil
IMIP - Instituto de Medicina Integral Professor Fernando Figueira
Pernambuco, , Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, , Brazil
Hospital de Clínicas de Porto Alegre - HCPA
Porto Alegre, , Brazil
HGB - Hospital Giovanni Battista/Mãe de Deus Center
Porto Alegre, , Brazil
Hospital São Lucas da PUCRS
Porto Alegre, , Brazil
Instituto Americas
Rio de Janeiro, , Brazil
Clínica de Oncologia de Porto Alegre Ltda - CLINIONCO
Rio Grande, , Brazil
Unidade de PesquisasClinicas em Oncologia - UPCO
Rio Grande, , Brazil
Instituto do Câncer - Hospital São Vicente de Paulo
Rio Grande, , Brazil
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
Santo André, , Brazil
Instituto Hemomed Oncologia e Hematologia
São Paulo, , Brazil
Clinica de pesquisa e centro de estudos em oncologia ginecológica e mamaria
São Paulo, , Brazil
BC Cancer - Kelowna
Kelowna, , Canada
The Ottawa Hospital Cancer Centre
Ottawa, , Canada
CHU de Québec-Université Laval, Hôpital du Saint-Sacrement
Québec, , Canada
Humber River Hospital
Toronto, , Canada
BC Cancer-Victoria
Victoria, , Canada
Centro de Investigacion Clinica Bradford Hill
Recoleta, , Chile
Centro del Cancer UC
Region Metropolitana, , Chile
Centro de Oncología de Precisión (COP)
Santiago Region, , Chile
James Lind Centro de Investigacion del Cancer
Temuco, , Chile
Oncocentro APYS
Viña del Mar, , Chile
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Anhui, , China
Peking University People's Hospital
Beijing, , China
The First Hospital of Jilin University
Changchun, , China
Xiangya Hospital Central South University
Changsha, , China
West China Hospital Sichuan University
Chengdu, , China
Chongqing University Cancer Hospital
Chongqing, , China
Fujian Cancer Hospital
Fujian, , China
Fujian Medical University Union Hospital
Fuzhou, , China
Sun Yat-Sen University Cancer Center
Guangdong, , China
Guangdong Provincial People's Hospital
Guangzhou, , China
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, , China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, , China
Sir Run Run Shaw Hospital,Zhejiang University School of Medicine
Hangzhou, , China
Zhejiang Cancer Hospital
Hangzhou, , China
Harbin Medical University Cancer Hospital
Heilongjiang, , China
Jiangsu Province Hospital
Jiangsu, , China
The First Affiliated Hospital of Soochow University
Jiangsu, , China
The Nanchang Third Hospital
Jiangxi, , China
The Second Hospital of Jilin University
Jilin Sheng, , China
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, , China
The First Affiliated Hospital of Nanchang University
Nanchang, , China
General Hospital of Ningxia Medical University
Ningxia Hui, , China
The Affiliated Hospital Of Qingdao University
Qingdao, , China
Fudan University Shanghai Cancer Center
Shanghai, , China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, , China
Hubei Cancer Hospital
Wuhan, , China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, , China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Zhejiang, , China
Henan Cancer Hospital
Zhengzhou, , China
Fakultni Nemocnice Brno
Brno, , Czechia
Masaryk Memorial Cancer Institute
Brno, , Czechia
University Hospital Olomouc
Olomouc, , Czechia
Multiscan s.r.o
Pardubice, , Czechia
Charles General University Hospital, Prague
Prague, , Czechia
Fakultni nemocnice v Motole
Prague, , Czechia
Krajska nemocnice Tomase Bati Zlin
Zlín, , Czechia
CHU Jean Minjoz
Besançon, , France
Institut Bergonié
Bordeaux, , France
Centre Georges François Leclerc
Dijon, , France
Centre Oscar Lambret
Lille, , France
Clinique Francois Chenieux
Limoges, , France
Ico René Gauducheau
Loire Atlantique, , France
Centre Leon Berard
Lyon, , France
Institut Paoli Calmettes
Marseille, , France
Institut Regional du Cancer de Montpellier
Montpellier, , France
Institut Curie
Paris, , France
Centre Hospitalier Lyon-Sud
Pierre-Bénite, , France
Hopital Privé des Cotes d'Armor
Plérin, , France
Centre Jean Bernard Service d'Oncologie Médicale
Rennes, , France
Centre Henri Becquerel
Rouen, , France
Institut Universitaire du Cancer de Toulouse Oncopole
Toulouse, , France
Institut Gustave Roussy
Villejuif, , France
Universitaetsklinikum Freiburg, Klinik fuer Frauenheilkunde
Baden-Württemberg, , Germany
University Hospital rechts der Isar Technical University of Munich
Bayern, , Germany
Vivantes Klinikum am Urban
Berlin, , Germany
HELIOS Klinikum Berlin-Buch
Berlin, , Germany
Marienhospital Bottrop
Bottrop, , Germany
Universitätsklinik Erlangen
Erlangen, , Germany
SRH Wald-Klinikum Gera GmbH
Gera, , Germany
Universitatsklinikum Hamburg-Eppendorf
Hamburg, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
Nationales Centrum für Tumorerkrankungen Heidelberg
Heidelberg, , Germany
Universitätsklinikum Mannheim
Mannheim, , Germany
LMU Klinikum der Universitat München
München, , Germany
Universitatsklinikum Munster
Münster, , Germany
Universitäts - Frauenklinik
Tübingen, , Germany
Alexandra General Hospital
Athens, , Greece
Attikon Hospital
Athens, , Greece
University Hospital of Heraklion
Heraklion, , Greece
University Hospital of Larissa
Larissa, , Greece
University Hospital of Patras
Pátrai, , Greece
Bioclinic of Thessaloniki
Thessaloniki, , Greece
Euromedica General Clinic of Thessaloniki
Thessaloniki, , Greece
Hong Kong Integrated Oncology Centre
Hong Kong, , Hong Kong
Prince of Wales Hospital
New Territories, , Hong Kong
Queen Mary Hospital
Pok Fu Lam, , Hong Kong
Semmelweis Egyetem, Belgyogyaszati es Onkologiai Klinika
Budapest, , Hungary
Debreceni Egyetem Klinikai Központ
Debrecen, , Hungary
Bács-Kiskun Varmegyei Oktatokorhaz, Onkaradiologiai Kozpont
Kecskemét, , Hungary
Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz, Onkoradiologia
Nyíregyháza, , Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
Szeged, , Hungary
Oncology Institute Rambam Health Care Campus
Haifa, , Israel
Shaare Zedek Medical Center
Jerusalem, , Israel
Hadassah Medical Center
Jerusalem, , Israel
Rabin Medical Center
Petah Tikva, , Israel
Sheba Medical Center
Ramat Gan, , Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, , Israel
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
Ancona AN, , Italy
Centro di Riferimento Oncologico - IRCCS
Aviano, , Italy
Humanitas Gavazzeni
Bergamo, , Italy
ASST Papa Giovanni XXIII
Bergamo, , Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola
Bologna, , Italy
Humanitas Istituto Clinico Catanese
Catania, , Italy
Azienda Ospedaliera Mater Domini
Catanzaro, , Italy
IRCCS Ospedale Policlinico San Martino
Genova GE, , Italy
Istituto Europeo di Oncologia
Milan, , Italy
Fondazione IRCCS San Raffaele del Monte Tabor
Milan, , Italy
Azienda Ospedaliera San Gerardo
Monza, , Italy
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Napoli, , Italy
Istituto Oncologico Veneto IOV
Padua, , Italy
Irccs Crob
Rionero in Vulture, , Italy
Azienda Ospedaliero-Universitaria Policlinico Umberto I
Roma, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, , Italy
Istituto Clinico Humanitas
Rozzano, , Italy
Aichi Cancer Center Hospital
Aichi, , Japan
Tohoku University Hospital
Aoba-ku, , Japan
Juntendo University Hospital
Bunkyō City, , Japan
Chiba Cancer Center
Chiba, , Japan
National Cancer Center Hospital
Chūōku, , Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Institute
Chūōku, , Japan
National Hospital Organization Shikoku Cancer Center
Ehime, , Japan
Fukushima Medical University Hospital
Fukushima, , Japan
Social Medical Corporation Hakuaikai Sagara Hospital
Kagoshima, , Japan
Tokai University Hospital
Kanagawa, , Japan
National Cancer Center Hospital East
Kashiwa, , Japan
Saitama Cancer Center
Kitaadachi-gun, , Japan
Cancer Institute Hospital of JFCR
Kōtoku, , Japan
Kumamoto University Hospital
Kumamoto, , Japan
Kyoto University Hospital
Kyoto, , Japan
National Hospital Organization Kyushu Cancer Center
Minamiku, , Japan
Nagoya University Hospital
Nagoya, , Japan
Hiroshima City Hiroshima Citizens Hospital
Nakaku, , Japan
Hyogo Medical University Hospital
Nishinomiya-shi, , Japan
Okayama University Hospital
Okayama, , Japan
Gunma Prefectural Cancer Center
Ōta-ku, , Japan
National Hospital Organization Hokkaido Cancer Center
Sapporo, , Japan
Center Hospital of the National Center for Global Health and Medicine
Shinjuku-ku, , Japan
Showa University Hospital
Tokyo, , Japan
Kanagawa Cancer Center
Yokohama, , Japan
Hospital Kuala Lumpur
Kuala Lumpur, , Malaysia
University Malaya Medical Centre
Kuala Lumpur, , Malaysia
Sarawak General Hospital
Kuching, , Malaysia
Institut Kanser Negara
Putrajaya, , Malaysia
Centro de Investigacion y Avances Medicos Especializados
Cancún, , Mexico
COI Centro Oncologico Internacional S.A.P.I. de C.V.
Mexico City, , Mexico
FUCAM
México, , Mexico
Hospital Universitario Dr. José Eleuterio González
Monterrey, , Mexico
Clinica Integral Internacional de Oncologia S de RL de CV
Puebla City, , Mexico
Centro Medico Zambrano Hellion
San Pedro Garza García, , Mexico
Centro de Atención e Investigación Clínica en Oncología
Yucatán, , Mexico
Copemicus Podmiot Leczniczy Wojewodzkie Centrum Okologii w Gdansku
Gdansk, , Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z.o.o
Krakow, , Poland
Instytut MSF Sp. z o.o.
Lodz, , Poland
Wojewodzki Szpital Specjalistyczny lm. Stefana Kardynala Wyszynsklego SPZOZ w Lublinie
Lublin, , Poland
LUX MED Onkologia Sp. Zo.o.
Warsaw, , Poland
Maria Sklodowska - Curie Institute of Oncology
Warsaw, , Poland
Centro Clinico Academico - Hospital de Braga
Braga, , Portugal
Hospital da Senhora da Oliveira Guimaraes
Guimarães, , Portugal
Centro Hospitalar de Lisboa Central, E.P.E . - Hospital de Santo Antonio dos Capuchos
Lisbon, , Portugal
Fundacao Champalimaud
Lisbon, , Portugal
Centro Hospitalar Lisboa Norte, EPE
Lisbon, , Portugal
Unidade Local de Saude de Matosinhos EPE - Hospital Pedro Hispano
Matosinhos Municipality, , Portugal
National University Hospital
Singapore, , Singapore
National Cancer Centre Singapore
Singapore, , Singapore
Tan Tock Seng Hospital
Singapore, , Singapore
Wilgers Oncology Centre
Gauteng, , South Africa
Wits Clinical Research
Johannesburg, , South Africa
The Medical Oncology Centre of Rosebank
Johannesburg, , South Africa
Cape Town Oncology Trials
Kraaifontein, , South Africa
Samsung Medical Center
Gangnam-Gu, , South Korea
National Cancer Center
Goyang-si Gyeonggi-do, , South Korea
Kyungpook National University Chilgok Hospital
Gyeongsangbuk-do, , South Korea
Gachon University Gil Medical Center
Incheon, , South Korea
Seoul National University Bundang Hospital
Seongnam, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Hospital Universitari Dexeus
Barcelona, , Spain
Hospital Clinic de Barcelona
Barcelona, , Spain
Hospital Universitari Vall D'Hebron
Barcelona, , Spain
Hospital de Basurto
Bilbao, , Spain
Hospital Universitario Reina Sofia
Córdoba, , Spain
Hospital General Universitario De Elche
Elche, , Spain
Hospital Universitario de Jaen
Jaén, , Spain
Hospital Beata María Ana
Madrid, , Spain
Hospital General Universitario Gregorio Marañón
Madrid, , Spain
MD Anderson Cancer Center
Madrid, , Spain
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Hospital Clinico San Carlos
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario de Salamanca
Salamanca, , Spain
Hospital Clínico Universitario de Santiago de Compostela - CHUS
Santiago de Compostela, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Hospital Universitario Virgen Macarena
Seville, , Spain
Instituto Valenciano De Oncologia (IVO)
Valencia, , Spain
Hospital Clínico Universitario de Valencia
Valencia, , Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, , Taiwan
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare
New Taipei City, , Taiwan
National Cheng Kung University Hospital
Tainan City, , Taiwan
Chi Mei Hospital, Liouying
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Tri-Service General Hospital
Taipei, , Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, , Taiwan
Chang Gung Memorial Hospital, Linkou
Taoyuan, , Taiwan
Barts Cancer Institute
London, , United Kingdom
University College London Hospitals
London, , United Kingdom
The Royal Marsden NHS Foundation Trust
London, , United Kingdom
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tarantino P, Tolaney SM, Curigliano G. Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. Ann Oncol. 2023 Oct;34(10):949-950. doi: 10.1016/j.annonc.2023.07.003. Epub 2023 Jul 26. No abstract available.
Related Links
Access external resources that provide additional context or updates about the study.
Gilead Clinical Trials Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-502593-17-00
Identifier Type: OTHER
Identifier Source: secondary_id
jRCT2061230032
Identifier Type: OTHER
Identifier Source: secondary_id
DOH-27-082023-6901
Identifier Type: OTHER
Identifier Source: secondary_id
MOH_2023-07-17_012821
Identifier Type: OTHER
Identifier Source: secondary_id
CTR20233370
Identifier Type: REGISTRY
Identifier Source: secondary_id
GS-US-598-6168
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.